|
AU4777896A
(en)
*
|
1995-02-10 |
1996-08-27 |
G.D. Searle & Co. |
Use of low dose amount of spironolactone for treatment of cardiovascular disease
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
FI20010233A0
(fi)
*
|
2001-02-08 |
2001-02-08 |
Orion Corp |
Menetelmä sydämen vajaatoiminnan hoitoon
|
|
FI20011464A0
(fi)
*
|
2001-07-04 |
2001-07-04 |
Orion Corp |
Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
|
|
US7020521B1
(en)
|
2002-11-08 |
2006-03-28 |
Pacesetter, Inc. |
Methods and apparatus for detecting and/or monitoring heart failure
|
|
MXPA06005518A
(es)
|
2003-11-17 |
2006-08-17 |
Novartis Ag |
Uso de inhibidores de la dipeptidil peptidasa iv.
|
|
JP2007514665A
(ja)
*
|
2003-12-12 |
2007-06-07 |
ミオゲン インコーポレイティッド |
エノキシモン製剤ならびに心肥大および心不全の治療へのそれらの使用方法
|
|
WO2005092333A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
US20060025463A1
(en)
*
|
2004-03-22 |
2006-02-02 |
Michael Bristow |
Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
|
|
EP1776108A1
(en)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
ATE469245T1
(de)
*
|
2004-09-14 |
2010-06-15 |
Univ Colorado |
Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol
|
|
EP1888101B1
(en)
|
2005-06-06 |
2012-03-21 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
WO2007014029A2
(en)
*
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
|
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
|
SG10202107533RA
(en)
*
|
2017-01-03 |
2021-08-30 |
Cardioxyl Pharmaceuticals Inc |
Method of administering nitroxyl donating compounds
|
|
JP2020527133A
(ja)
|
2017-06-20 |
2020-09-03 |
インブリア ファーマシューティカルズ， インコーポレイテッド |
心臓代謝の効率を高めるための組成物および方法
|
|
WO2021225950A1
(en)
*
|
2020-05-04 |
2021-11-11 |
Imbria Pharmaceuticals, Inc. |
Dosing methods for treatment of cardiovascular conditions
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|
